Xenomics, Inc. has announced that it has obtained exclusive rights to use a recently discovered genetic marker for Acute Myeloid Leukemia (AML) for the development of diagnostic tools.
"The identification of this genetic marker will permit physicians to diagnose AML earlier and develop more effective treatment plans," said Dr. Moshe Talpaz, a specialist in hematology & oncology with the Department of Internal Medicine at the University of Michigan Health System. "This is a major discovery."
"This newly discovered marker is a major advance in the diagnosis of AML which I intend to use in my practice," said Dr. Hagop Kantarjian, Chairman, Department of Leukemia, MS Anderson Cancer Center.
"The PCR test for detecting the genetic marker has already been used in samples of bone marrow and peripheral blood from many patients with AML resulting in increased diagnostic accuracy and better monitoring of the disease," said Drs. Cristina Mecucci and Brunangelo Falini, collaborators at the Institute of Hematology at the University of Perugia in Italy.
"We are delighted that our efforts can result in such a positive impact upon the quality of life for so many individuals throughout the world."
"The Xenomics management team intends to use its clinical experience and extensive network with the world's leading hematologists to assist in the commercial development of this important discovery," said Gabriele M. Cerrone, Co-Chairman of Xenomics.
"Certainly the discovery of the new genetic marker will be critically important to physicians because it can provide a diagnostic tool to classify the type of AML much more rapidly than conventional techniques," commented Dr. David Tomei, CEO and Co-Founder of Xenomics.